185 related articles for article (PubMed ID: 23851114)
21. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Marighetti F; Steggemann K; Hanl M; Wiese M
ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
23. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
Stefan K; Schmitt SM; Wiese M
J Med Chem; 2017 Nov; 60(21):8758-8780. PubMed ID: 29016119
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Pick A; Müller H; Wiese M
Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters.
Dankó B; Tóth S; Martins A; Vágvölgyi M; Kúsz N; Molnár J; Chang FR; Wu YC; Szakács G; Hunyadi A
ChemMedChem; 2017 Jun; 12(11):850-859. PubMed ID: 28436164
[TBL] [Abstract][Full Text] [Related]
27. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
J Med Chem; 2016 Apr; 59(7):3018-33. PubMed ID: 26943020
[TBL] [Abstract][Full Text] [Related]
28. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
29. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
[TBL] [Abstract][Full Text] [Related]
30. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
Liu XL; Tee HW; Go ML
Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
33. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
34. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
[TBL] [Abstract][Full Text] [Related]
35. Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
Zhu X; Wong ILK; Chan KF; Cui J; Law MC; Chong TC; Hu X; Chow LMC; Chan TH
J Med Chem; 2019 Sep; 62(18):8578-8608. PubMed ID: 31465686
[TBL] [Abstract][Full Text] [Related]
36. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Sim HM; Lee CY; Ee PL; Go ML
Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
[TBL] [Abstract][Full Text] [Related]
37. Scaffold identification of a new class of potent and selective BCRP inhibitors.
Marighetti F; Steggemann K; Karbaum M; Wiese M
ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
[TBL] [Abstract][Full Text] [Related]
38. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
Ahmed-Belkacem A; Pozza A; Macalou S; Pérez-Victoria JM; Boumendjel A; Di Pietro A
Anticancer Drugs; 2006 Mar; 17(3):239-43. PubMed ID: 16520651
[TBL] [Abstract][Full Text] [Related]
40. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]